Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CMPS 
Compass Pathways Plc (CMPS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CMPS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -29.97% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 286.36M USD | Price to earnings Ratio - | 1Y Target Price 17.56 |
Price to earnings Ratio - | 1Y Target Price 17.56 | ||
Volume (30-day avg) 1069251 | Beta 2.29 | 52 Weeks Range 2.69 - 10.31 | Updated Date 04/2/2025 |
52 Weeks Range 2.69 - 10.31 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -40.11% | Return on Equity (TTM) -81.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 125670038 | Price to Sales(TTM) - |
Enterprise Value 125670038 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.51 | Shares Outstanding 92673104 | Shares Floating 71549218 |
Shares Outstanding 92673104 | Shares Floating 71549218 | ||
Percent Insiders 14.11 | Percent Institutions 42.99 |
Analyst Ratings
Rating 4.6 | Target Price 21.22 | Buy 4 | Strong Buy 6 |
Buy 4 | Strong Buy 6 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Compass Pathways Plc
Company Overview
History and Background
Compass Pathways Plc was founded in 2016 and is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. It focuses on developing psychedelic therapies, initially for treatment-resistant depression.
Core Business Areas
- Drug Development: Researching and developing psychedelic therapies, particularly psilocybin, for mental health disorders.
- Clinical Trials: Conducting clinical trials to assess the safety and efficacy of their therapies.
- Healthcare Innovation: Advancing the understanding and treatment of mental health conditions.
Leadership and Structure
The leadership team consists of experienced professionals in drug development, clinical research, and business strategy. The company has a typical corporate structure with a board of directors and various departments focusing on research, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- COMP360 (Psilocybin therapy): COMP360 is Compass Pathways' lead investigational drug, a proprietary formulation of psilocybin. It is currently undergoing Phase III clinical trials for treatment-resistant depression (TRD). Market share data is not yet available due to it not being approved. Competitors in the psychedelic therapy space include Atai Life Sciences (ATAI), GH Research (GHRS), and Mind Medicine (MNMD).
Market Dynamics
Industry Overview
The mental health market is substantial and growing, driven by increasing awareness and prevalence of mental health disorders. There's growing interest in psychedelic-assisted therapies for treatment-resistant conditions.
Positioning
Compass Pathways is a leading company in the development of psilocybin therapy for TRD. Their competitive advantage lies in their clinical trial progress and proprietary formulation of psilocybin.
Total Addressable Market (TAM)
The TAM for depression treatment is estimated to be in the tens of billions of dollars annually. Compass Pathways aims to capture a significant portion of this market with its novel therapy, COMP360.
Upturn SWOT Analysis
Strengths
- First-mover advantage in psilocybin therapy for TRD
- Strong intellectual property position
- Experienced management team
- Advanced clinical trial progress
Weaknesses
- Reliance on a single lead product (COMP360)
- High cash burn rate due to ongoing clinical trials
- Regulatory uncertainty surrounding psychedelic therapies
- Lack of approved product driving revenue
Opportunities
- Potential for regulatory approval of COMP360
- Expansion into other mental health indications
- Partnerships with healthcare providers
- Increased awareness and acceptance of psychedelic therapies
Threats
- Clinical trial failures
- Competition from other companies developing psychedelic therapies
- Regulatory hurdles and delays
- Negative public perception of psychedelics
Competitors and Market Share
Key Competitors
- ATAI
- GHRS
- MNMD
Competitive Landscape
Compass Pathways has a first-mover advantage but faces increasing competition. Success depends on demonstrating superior efficacy and safety, securing regulatory approvals, and building a strong commercial infrastructure.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Compass Pathways' historical growth is characterized by increasing investment in research and development and expansion of its clinical trial program.
Future Projections: Future growth is contingent on the successful completion of clinical trials and regulatory approval of COMP360. Analyst estimates vary depending on the perceived likelihood of approval and market adoption.
Recent Initiatives: Recent initiatives include advancing Phase III clinical trials for COMP360, exploring new mental health indications, and engaging with regulators to clarify the approval pathway for psychedelic therapies.
Summary
Compass Pathways is a clinical-stage biopharmaceutical company focused on developing psilocybin therapy for treatment-resistant depression. Its success hinges on the positive outcomes of its ongoing Phase III clinical trials and subsequent regulatory approval. The company is in a very high risk high reward position since it does not have any sales or revenue and is burning though cash to fund expensive trials. The company needs to watch out for any negative data coming from clinical trials and its overall burn rate.
Similar Companies
ATAI
ATAI Life Sciences BV
ATAI
ATAI Life Sciences BV
GHRS
GH Research PLC
GHRS
GH Research PLC
MNMD
Mind Medicine Inc
MNMD
Mind Medicine Inc
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Company Press Releases
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The information provided is based on publicly available data, which may be subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Compass Pathways Plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-09-18 | CEO & Director Mr. Kabir Kumar Nath M.A., M.B.A. | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 166 | Website https://compasspathways.com |
Full time employees 166 | Website https://compasspathways.com | ||
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.